We are live on ! Find out more
RVLP

RVL Pharmaceuticals plc Ordinary Shares
RVLP

Delisted

RVLP was delisted on the 20th of October, 2023.

Back to rankings

46 hedge funds and large institutions have $14.5M invested in RVL Pharmaceuticals plc Ordinary Shares in 2021 Q2 according to their latest regulatory filings, with 10 funds opening new positions, 6 increasing their positions, 22 reducing their positions, and 19 closing their positions.

New
Increased
Maintained
Reduced
Closed

16% less funds holding

Funds holding: 55 → 46 (-9)

43% less capital invested

Capital invested by funds: $25.6M → $14.5M (-$11.1M)

47% less first-time investments, than exits

New positions opened: 10 | Existing positions closed: 19

73% less repeat investments, than reductions

Existing positions increased: 6 | Existing positions reduced: 22

Holders
46
Holders Change
-9
Holders Change %
-16.36%
% of All Funds
0.8%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
10
Increased
6
Reduced
22
Closed
19
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
RA
Rovida Advisors
Florida
+$919K
2
Millennium Management
Millennium Management
New York
+$490K
3
E
Ergoteles
New York
+$175K
4
HF
HRT Financial
New York
+$110K
5
HW
Hancock Whitney
Mississippi
+$108K

Top Sellers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
-$3.52M
2
SCM
Sio Capital Management
New York
-$1.69M
3
WCM
Wedge Capital Management
North Carolina
-$1.11M
4
Morgan Stanley
Morgan Stanley
New York
-$802K
5
AllianceBernstein
AllianceBernstein
Tennessee
-$703K
Name Holding Trade Value Shares
Change 		Change in
Stake
Morgan Stanley
1
Morgan Stanley
New York
$5.02M -$802K -262,130 -14%
Renaissance Technologies
2
Renaissance Technologies
New York
$2.93M +$20.2K +6,595 +0.7%
Jacobs Levy Equity Management
3
Jacobs Levy Equity Management
New Jersey
$1.02M -$213K -69,489 -17%
RA
4
Rovida Advisors
Florida
$901K +$919K +300,308 New
Vanguard Group
5
Vanguard Group
Pennsylvania
$634K -$177K -57,973 -22%
BlackRock
6
BlackRock
New York
$503K -$3.52M -1,150,685 -87%
Millennium Management
7
Millennium Management
New York
$482K +$490K +160,140 New
Geode Capital Management
8
Geode Capital Management
Massachusetts
$468K -$260K -85,013 -35%
Squarepoint
9
Squarepoint
New York
$243K -$261K -85,336 -51%
Charles Schwab
10
Charles Schwab
California
$187K -$73.1K -23,870 -28%
Marshall Wace
11
Marshall Wace
United Kingdom
$174K -$121K -39,607 -41%
Dimensional Fund Advisors
12
Dimensional Fund Advisors
Texas
$172K -$12.3K -4,016 -7%
E
13
Ergoteles
New York
$172K +$175K +57,200 New
Goldman Sachs
14
Goldman Sachs
New York
$169K +$19.8K +6,455 +13%
HW
15
Hancock Whitney
Mississippi
$162K +$108K +35,255 +191%
Deutsche Bank
16
Deutsche Bank
Germany
$159K -$23.9K -7,795 -13%
JP Morgan Chase
17
JP Morgan Chase
New York
$113K +$92.9K +30,341 +418%
HF
18
HRT Financial
New York
$108K +$110K +36,061 New
EGM
19
Engineers Gate Manager
New York
$105K -$78.2K -25,560 -42%
Jane Street
20
Jane Street
New York
$105K +$107K +35,028 New
State Street
21
State Street
Massachusetts
$91K -$546K -178,419 -85%
IA
22
Insight Advisors
Pennsylvania
$85K – – –
CS
23
Credit Suisse
Switzerland
$84K +$85.6K +27,966 New
Northern Trust
24
Northern Trust
Illinois
$79K -$362K -118,377 -82%
ZCM
25
Zebra Capital Management
Connecticut
$73K – – –
1
2 3

RVLP Hedge Fund Activity: Q2 2021 in Review

46 of the 5,746 institutional investors tracked by Wall St. Rank reported a position in RVL Pharmaceuticals plc Ordinary Shares (RVLP) for Q2 2021, worth a combined $14.5M — down 43% from $25.6M a quarter earlier.

Sellers outnumbered buyers: 19 funds closed out of RVLP and 10 opened new positions — a net loss of 9 holders — while 22 trimmed existing stakes and 6 added.

The largest buyer was Rovida Advisors, opening a new position worth an estimated $919K. The largest seller was BlackRock, cutting an estimated $3.52M.

  • 46 institutional investors held RVL Pharmaceuticals plc Ordinary Shares (RVLP) as of Q2 2021, down from 55 in Q1 2021.
  • Funds reported $14.5M of RVL Pharmaceuticals plc Ordinary Shares stock for Q2 2021, down 43% quarter-over-quarter.
  • 10 funds opened new RVL Pharmaceuticals plc Ordinary Shares positions in Q2 2021 and 19 closed out, a net change of -9 holders.
  • The largest RVL Pharmaceuticals plc Ordinary Shares buyer in Q2 2021 was Rovida Advisors, an estimated $919K added.
  • The largest RVL Pharmaceuticals plc Ordinary Shares seller in Q2 2021 was BlackRock, an estimated $3.52M sold.

Based on aggregated 13F filings for Q2 2021.